Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial.

Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching PA, Sinn BV, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young B, Hanusch CA, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S.

Clin Cancer Res. 2020 Jan 13. pii: clincanres.1954.2019. doi: 10.1158/1078-0432.CCR-19-1954. [Epub ahead of print]

PMID:
31932495
2.

Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.

Sun Y, Lin X, Aske JC, Ye P, Williams C, Abramovitz M, Leyland-Jones BR.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1241-1256. doi: 10.1007/s00280-019-03962-8. Epub 2019 Sep 20.

PMID:
31541266
3.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

4.

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber RD, Dowsett M, Leyland-Jones B, Piccart-Gebhart MJ, DE Azambuja E.

Anticancer Res. 2019 Feb;39(2):797-802. doi: 10.21873/anticanres.13177.

PMID:
30711959
5.

RET rearrangements are actionable alterations in breast cancer.

Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S, Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM.

Nat Commun. 2018 Nov 16;9(1):4821. doi: 10.1038/s41467-018-07341-4.

6.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

7.

RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue.

Forster M, Mark A, Egberts F, Rosati E, Rodriguez E, Stanulla M, Bauerschlag D, Schem C, Maass N, Amallraja A, Murphy KK, Prouse BR, Sulaiman RA, Young BM, Mathiak M, Hemmrich-Stanisak G, Ellinghaus D, Weidinger S, Rosenstiel P, Arnold N, Leyland-Jones B, Williams CB, Franke A, Meißner T.

Oncotarget. 2018 Aug 17;9(64):32362-32372. doi: 10.18632/oncotarget.25981. eCollection 2018 Aug 17.

8.

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells.

De P, Carlson JH, Leyland-Jones B, Williams C, Dey N.

Sci Rep. 2018 Sep 4;8(1):13192. doi: 10.1038/s41598-018-31575-3.

9.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

10.

Promise of Precision Medicine in Cancers: Lessons Learned.

Dey N, Williams C, Leyland-Jones B, De P.

S D Med. 2017 Nov;70(11):486-490. No abstract available.

PMID:
29088519
11.

Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient.

Xu B, Krie A, De P, Williams C, Elsey R, Klein J, Leyland-Jones B.

Cureus. 2017 Jun 29;9(6):e1408. doi: 10.7759/cureus.1408.

12.

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.

Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.

13.

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.

14.

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Dey N, Krie A, Klein J, Williams K, McMillan A, Elsey R, Sun Y, Williams C, De P, Leyland-Jones B.

Int J Mol Sci. 2017 Jun 7;18(6). pii: E1218. doi: 10.3390/ijms18061218.

15.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

16.

Mutation matters in precision medicine: A future to believe in.

Dey N, Williams C, Leyland-Jones B, De P.

Cancer Treat Rev. 2017 Apr;55:136-149. doi: 10.1016/j.ctrv.2017.03.002. Epub 2017 Mar 16. Review.

PMID:
28371665
17.

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.

Dey N, De P, Leyland-Jones B.

Pharmacol Ther. 2017 Jul;175:91-106. doi: 10.1016/j.pharmthera.2017.02.037. Epub 2017 Feb 16. Review.

PMID:
28216025
18.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team.

Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Erratum in: Lancet. 2019 Mar 16;393(10176):1100.

19.

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.

De P, Carlson JH, Jepperson T, Willis S, Leyland-Jones B, Dey N.

Oncotarget. 2017 Jan 10;8(2):3072-3103. doi: 10.18632/oncotarget.13618.

20.

Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy.

Abramovitz M, Krie A, Dey N, De P, Williams C, Leyland-Jones B.

Curr Opin Oncol. 2016 Nov;28(6):461-468. Review.

PMID:
27606693

Supplemental Content

Loading ...
Support Center